Inspire Medical’s Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
BofA Securities has upgraded Inspire Medical Systems, Inc. (NYSE:INSP) and says the company now falls in the profitable growth category.
Inspire Medical is expected to give its 2025 revenue guidance in early January, likely alongside its fourth-quarter results.
The company has already stated that it is comfortable with the Street’s consensus of $950 million in revenue for 2025.
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.
BofA has upgraded the stock from Neutral to Buy with a price target of $255, up from $220.
Inspire Medical’s outlook for 2025 is based on plans to hire more staff, open new centers, …
Full story available on Benzinga.com